首页> 外文期刊>Therapeutic Drug Monitoring >Correlation of levetiracetam concentrations between serum and saliva.
【24h】

Correlation of levetiracetam concentrations between serum and saliva.

机译:血清和唾液中左乙拉西坦浓度的相关性。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: More than 100 drugs have been evaluated for salivary therapeutic drug monitoring since the 1970s. The most studied drugs are the anticonvulsants phenytoin, phenobarbital, and carbamazepine, demonstrating strong correlations between serum and saliva concentrations. No published data exist for levetiracetam (LEV) to the authors' knowledge. This study's objective is to determine the correlation between LEV serum and saliva concentrations. METHODS: Investigators identified subjects seen in neurology clinics at the University of Kentucky. Patients were eligible if they agreed to participate in this study, were taking LEV for a minimum of 4 weeks, and if a serum LEV concentration had been ordered by their physician. Patients spit a minimum of 0.25 mL into a cup to obtain saliva samples. Blood samples were obtained by phlebotomy. RESULTS: Serum and saliva LEV concentrations were determined via high-performance liquid chromatography (HPLC) in two separate reference laboratories. Linear regression analysis was used to evaluate correlations. Serum and saliva samples were obtained from 40 patients (22 female, 18 male), ranging from 3 to 57 years of age. The mean +/- SD serum LEV concentration for reference laboratory A was significantly lower (P < 0.0001) than reference laboratory B, 23.6 +/- 13.8 microg/mL and 27.0 +/- 16.9 microg/mL, respectively. The mean +/- SD saliva to serum concentration fraction was also different for the two laboratories, i.e., 41.0% +/- 0.15% for lab A and 36.0% +/- 0.15% for lab B (P = 0.001). The correlation coefficients for the two laboratories were similar, 0.87 and 0.86 (both P < 0.0001) for labs A and B, respectively. CONCLUSION: A significant positive correlation exists between LEV saliva and serum concentrations. The ability to monitor LEV therapy using saliva may provide benefits that include facilitating sample collection and improving the quality of life for persons with epilepsy. Patients with poor venous access, such as children and elderly patients, and persons afraid of needles may particularly benefit from this method.
机译:目的:自1970年代以来,已经评估了100多种药物用于唾液治疗药物监测。研究最多的药物是抗惊厥药苯妥英钠,苯巴比妥和卡马西平,证明血清和唾液浓度之间存在很强的相关性。据作者所知,尚无左乙拉西坦(LEV)的公开数据。这项研究的目的是确定LEV血清和唾液浓度之间的相关性。方法:研究人员确定了在肯塔基大学神经内科诊所见过的受试者。如果患者同意参加本研究,服用LEV至少4周并且其医师已订购血清LEV浓度,则患者符合条件。患者将至少0.25 mL吐入杯中以获取唾液样本。通过放血获得血液样品。结果:在两个独立的参考实验室中,通过高效液相色谱(HPLC)测定了血清和唾液中LEV的浓度。线性回归分析用于评估相关性。从3至57岁的40位患者(22位女性,18位男性)中获取血清和唾液样本。参考实验室A的平均+/- SD血清LEV浓度显着低于参考实验室B(P <0.0001),分别为23.6 +/- 13.8 microg / mL和27.0 +/- 16.9 microg / mL。两个实验室的平均+/- SD唾液至血清浓度分数也有所不同,即实验室A为41.0%+/- 0.15%,实验室B为36.0%+/- 0.15%(P = 0.001)。两个实验室的相关系数相似,实验室A和B的相关系数分别为0.87和0.86(均P <0.0001)。结论:LEV唾液与血清浓度呈显着正相关。使用唾液监测LEV治疗的能力可能会带来好处,包括促进样本采集和改善癫痫患者的生活质量。静脉通路较差的患者(例如儿童和老年患者)以及不敢穿针的人可能会特别受益于此方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号